The magnitude of neurocognitive disorders and associated factors among people living with HIV AIDS facilities in Bahir Dar City Ethiopia.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 Aug 2024
Historique:
received: 19 01 2024
accepted: 29 07 2024
medline: 18 8 2024
pubmed: 18 8 2024
entrez: 17 8 2024
Statut: epublish

Résumé

Neurocognitive disorders are mental health conditions that are caused by medical illnesses and can lead to several acquired cognitive deficits, which represent a decline from a previously attained level of functioning. The principal domains of cognitive functions include complex attention, executive function, learning and memory, language, perceptual-motor function, and social cognition. Studies have shown that people living with human immunodeficiency virus (HIV) are at a heightened risk of experiencing cognitive challenges across multiple domains. Given that, a substantial number of people live in Amhara region, assessing cognitive domains to estimate the current magnitude and factors associated with neurocognitive disorders among HIV/AIDS patients is crucial. An institutional-based cross-sectional study was conducted among 569 participants adults living with HIV attending the city's selected health facilities from March 20 to April 30, 2023. A multistage sampling technique was used. The International HIV Dementia Scale (IHDS) was used to measure the outcome of interest. The data were collected using a structured questionnaire and document review. The data were analyzed using STATA version 14. Multiple binary logistic regressions were used as the final model. A total of 501 individuals, with a response rate of 88.04% participated in the study. The overall proportion of HIV patients with neurocognitive impairment was 54.7% (95% CI 50.62-58.77). Factors associated with the neurocognitive impairment were: being widowed AOR = 3.05 (95% CI 1.47-6.31), divorced AOR = 1.95 (1.16-3.28), rural residence AOR = 2.28 (95% CI 1.02-5.09), CD4 count below 500 cells/dl AOR = 1.61 (95% CI 1.03-2.50), history of opportunistic infection AOR = 2.21 (95% CI 1.42-3.41), being in first-line drug regimen AOR = 2.92 (95% CI 1.22-7.00), being in a first-line regimen with Efavirenz AOR = 4.36 (95% CI 1.07-17.73), and impairment in daily living AOR = 2.64 (95% CI 1.39-4.99). In this study, the proportion of neurocognitive impairment was greater than that in most previous studies conducted in Ethiopia. The factors associated with the disorder were: being widowed or divorced, living in a rural area, having low CD4, having a history of opportunistic infection, receiving a first-line drug regimen, receiving efavirenz-containing drugs, and having impaired daily living. Hence, routine neuropsychological screenings should be integrated into comprehensive ART care by the regional health bureau and implemented by hospitals and health centers.

Identifiants

pubmed: 39154066
doi: 10.1038/s41598-024-68909-3
pii: 10.1038/s41598-024-68909-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19058

Informations de copyright

© 2024. The Author(s).

Références

National library of medicine, Neurocognitive disorder. Medline plus found at https://medlineplus.gov 2022.
Belete, T., Medfu, G. & Yemiyamrew, E. Prevalence of HIV associated neurocognitive deficit among HIV positive people in Ethiopia: A cross sectional study at Ayder Referral Hospital. Ethiop. J. Health Sci. 27(1), 67–76 (2017).
doi: 10.4314/ejhs.v27i1.9 pubmed: 28458492 pmcid: 5390230
McArthur, J. C. et al. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann. Neurol. 67(6), 699–714 (2010).
doi: 10.1002/ana.22053 pubmed: 20517932
Weill institute for neuro sciences, A healthcare providers guide to HIV associated neurocognitive disorder (HAND). UCSF HIV dementia providers, 2017.
Ciccarelli, N. Considerations on nosology for HIV-associated neurocognitive disorders: It is time to update?. Infection 48(1), 37–42 (2020).
doi: 10.1007/s15010-019-01373-8 pubmed: 31691905
Clifford, D. B. HIV-associated neurocognitive disorder. Curr. Opin. Infect. Dis. 30(1), 117–122 (2017).
doi: 10.1097/QCO.0000000000000328 pubmed: 27798498 pmcid: 5382956
Saylor, D. et al. HIV-associated neurocognitive disorder—Pathogenesis and prospects for treatment. Nat. Rev. Neurol. 12(4), 234–248 (2016).
doi: 10.1038/nrneurol.2016.27 pubmed: 26965674 pmcid: 4937456
Ances, B.M. and R.J. Ellis. Dementia and neurocognitive disorders due to HIV-1 infection. in Seminars in neurology. 2007. Copyright© 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New
Zenebe, Y. et al. A systematic review and meta-analysis of HIV associated neurocognitive disorders (HAND) among people with HIV in Ethiopia. AIDS Res. Ther. 18(1), 99 (2021).
doi: 10.1186/s12981-021-00424-1 pubmed: 34924002 pmcid: 8684693
Yitbarek, G. Y. et al. Cognitive impairment and its associated factors among HIV/AIDS patients on anti retro -viral therapy in Sub-Saharan Africa: Systematic review and meta-analysis. Neurol. Psychiatry Brain Res. 38, 83–91 (2020).
doi: 10.1016/j.npbr.2020.11.002
Araya, T., et al. Prevalence and factors associated with neuro cognitive disorders among HIV-positive patients in Ethiopia: A hospital-based cross-sectional study. Ethiop. J. Health Develop. 34(1) (2020).
Lohse, N. et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann. Intern. Med. 146(2), 87–95 (2007).
doi: 10.7326/0003-4819-146-2-200701160-00003 pubmed: 17227932
Worku, W. Z. et al. HIV is still a major public health problem among pregnant women attending ANC in Referral Hospitals of the Amhara Regional State, Ethiopia: A cross sectional study. BMC Women’s Health 22(1), 468 (2022).
doi: 10.1186/s12905-022-02059-4 pubmed: 36434557 pmcid: 9701049
Worku, E. D., Asemahagn, M. A. & Endalifer, M. L. Epidemiology of HIV infection in the Amhara Region of Ethiopia, 2015 to 2018 surveillance data analysis. HIV AIDS (Auckl) 12, 307–314 (2020).
pubmed: 32801929
Trickey, A. et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV 4(8), e349–e356 (2017).
doi: 10.1016/S2352-3018(17)30066-8
Vivithanaporn, P. et al. Neurologic disease burden in treated HIV/AIDS predicts survival: A population-based study. Neurology 75(13), 1150–1158 (2010).
doi: 10.1212/WNL.0b013e3181f4d5bb pubmed: 20739646 pmcid: 3013488
Wei, J. et al. The prevalence of frascati-criteria-based HIV-associated neurocognitive disorder (hand) in HIV-infected adults: A systematic review and meta-analysis. Front. Neurol. 11, 581346 (2020).
doi: 10.3389/fneur.2020.581346 pubmed: 33335509 pmcid: 7736554
Mohamed, A. A., Oduor, C. & Kinyanjui, D. HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya. BMC Neurol. 20(1), 1–11 (2020).
doi: 10.1186/s12883-020-01857-3
Rumbaugh, J. A. & Tyor, W. HIV-associated neurocognitive disorders: Five new things. Neurol. Clin. Pract. 5(3), 224–231 (2015).
doi: 10.1212/CPJ.0000000000000117 pubmed: 26124979 pmcid: 4469345
Gisslén, M., Price, R. W. & Nilsson, S. The definition of HIV-associated neurocognitive disorders: Are we overestimating the real prevalence?. BMC Infectious Diseases 11(1), 356 (2011).
doi: 10.1186/1471-2334-11-356 pubmed: 22204557 pmcid: 3260107
Federal democratic republic of Ethiopia, M.o.H., Guidelines on clinical and programmatic management of major non communicable disease. National NCD guideline, 2016, 2016. https://extranet.who.int >ncdccs>Data>ETH_D1.
Ethiopian Federal Ministry of Health, National Comprehensive HIV Care Guideline 2018 2018. will be found at WHO Africa. https://www.afro.who.int >sites>default>files>
Daniel, B., et al., Psychometric Properties of the Montreal Cognitive Assessment (MoCA) to Detect Major Neurocognitive Disorder Among Older People in Ethiopia: A Validation Study. Neuropsychiatric Disease and Treatment, 2022: p. 1789–1798.
MoCA Basic administration and scoring instruction. to be found at https://catch-on.org/wp-content/uploads/2016/12/MoCA-Basic-Instructions.pdf , 2016.
Kroenke, K. et al. An ultrabrief screening scale for anxiety and depression: The PHQ-4. Psychosomatics 50(6), 613–621 (2009).
pubmed: 19996233
Graf, C. The Lawton instrumental activities of daily living scale. AJN Am. J. Nursing. 108(4) (2008).
Kocalevent, R.-D. et al. Social support in the general population: Standardization of the Oslo social support scale (OSSS-3). BMC Psychol. 6(1), 31 (2018).
doi: 10.1186/s40359-018-0249-9 pubmed: 30016997 pmcid: 6050647
Nweke, M. C. et al. Meta-analysis of factors affecting prevalence estimates of HIV-associated neurocognitive disorder in sub-Saharan Africa. S. Afr. J. Sci. 117, 1–10 (2021).
doi: 10.17159/sajs.2021/8575
Troncoso, F.T. and L.d.O. Conterno. Prevalence of neurocognitive disorders and depression in a Brazilian HIV population. Revista da Sociedade Brasileira de Medicina Tropical. 48, 390–398 (2015).
Zenebe, Y. et al. Worldwide occurrence of HIV-associated neurocognitive disorders and its associated factors: A systematic review and meta-analysis. Front. Psychiatry 13, 814362 (2022).
doi: 10.3389/fpsyt.2022.814362 pubmed: 35711575 pmcid: 9193596
Tsegaw, M. et al. Screening HIV-associated neurocognitive disorders (HAND) among HIV positive patients attending antiretroviral therapy in South Wollo, Ethiopia. J. Psychiatric Res. 85, 37–41 (2017).
doi: 10.1016/j.jpsychires.2016.10.016
Wubetu, A. D., Asefa, K. K. & Gebregiorgis, B. G. Prevalence of neurocognitive impairment and associated factors among people living with HIV on highly active antiretroviral treatment, Ethiopia. HIV AIDS (Auckl) 13, 425–433 (2021).
pubmed: 33889028
Eaton, P. et al. Risk factors for symptomatic HIV-associated neurocognitive disorder in adults aged 50 and over attending a HIV clinic in Tanzania. Int. J. Geriatr. Psychiatry 35(10), 1198–1208 (2020).
doi: 10.1002/gps.5357 pubmed: 32497330
Yusuf, A. J. et al. Prevalence of HIV-associated neurocognitive disorder (HAND) among patients attending a tertiary health facility in Northern Nigeria. J. Int. Assoc. Provid. AIDS Care 16(1), 48–55 (2017).
doi: 10.1177/2325957414553839 pubmed: 25331222
Gascón, M. R. P. et al. Neuropsychological assessment of 412 HIV-infected individuals in São Paulo, Brazil. AIDS Patient Care STDs 32(1), 1–8 (2018).
doi: 10.1089/apc.2017.0202 pubmed: 29323557
Debalkie Animut, M. et al. High prevalence of neurocognitive disorders observed among adult people living with HIV/AIDS in Southern Ethiopia: A cross-sectional study. PLoS One 14(3), e0204636 (2019).
doi: 10.1371/journal.pone.0204636 pubmed: 30883557 pmcid: 6422272
Kaleebu, P. et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J. Infect. .Dis 185(9), 1244–1250 (2002).
doi: 10.1086/340130 pubmed: 12001041
Kiros, M. et al. Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia. Retrovirology 17(1), 33 (2020).
doi: 10.1186/s12977-020-00542-0 pubmed: 32993693 pmcid: 7526103
Shin, S. H., Kim, G. & Park, S. Widowhood status as a risk factor for cognitive decline among older adults. Am. J. Geriatr. Psychiatry 26(7), 778–787 (2018).
doi: 10.1016/j.jagp.2018.03.013 pubmed: 29748078
Grov, C., Golub, S. A., Parsons, J. T., Brennan, M. & Karpiak, S. E. Loneliness and HIV-related stigma explain depression among older HIV-positive adults. AIDS Care. 22(5), 630–639. https://doi.org/10.1080/09540120903280901 (2010) (PMID: 20401765).
doi: 10.1080/09540120903280901 pubmed: 20401765 pmcid: 2936670
Namagga, J. K., Rukundo, G. Z. & Voss, J. G. Prevalence and risk factors of HIV-associated neurocognitive disorders in Rural Southwestern Uganda. J. Assoc. Nurses AIDS Care 30(5), 531–538 (2019).
doi: 10.1097/JNC.0000000000000036 pubmed: 31461736 pmcid: 6716529
Peritogiannis, V., et al. Mild cognitive impairment in rural areas: Research advances and implications for clinical practice and healthcare policy. Healthcare (Basel). 10(7) (2022).
Schouten, J. et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. Aids 30(7), 1027–1038 (2016).
doi: 10.1097/QAD.0000000000001017 pubmed: 26752277
Olivier, I. S., Cacabelos, R. & Naidoo, V. Risk factors and pathogenesis of HIV-associated neurocognitive disorder: The role of host genetics. Int. J. Mol. Sci. 19(11), 3594 (2018).
doi: 10.3390/ijms19113594 pubmed: 30441796 pmcid: 6274730
Valcour, V. et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection—The Hawaii Aging with HIV Cohort. J. Neurovirol. 12(5), 387–391 (2006).
doi: 10.1080/13550280600915339 pubmed: 17065131
Mossie, T. B. & Tegegne, M. T. HIV dementia among HIV positive people at Debre markos hospital, Northwest Ethiopia. Am. J. Psychol. Neurosci. 2(2), 18–24 (2014).
doi: 10.11648/j.ajpn.20140202.11
Nweke, M. et al. Impact of HIV-associated cognitive impairment on functional independence, frailty and quality of life in the modern era: A meta-analysis. Sci. Rep. 12(1), 6470 (2022).
doi: 10.1038/s41598-022-10474-8 pubmed: 35440802 pmcid: 9019017
Heaton, R. K. et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J. NeuroVirol. 17(1), 3–16 (2011).
doi: 10.1007/s13365-010-0006-1 pubmed: 21174240
Ciccarelli, N. et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76(16), 1403–1409 (2011).
doi: 10.1212/WNL.0b013e31821670fb pubmed: 21502598
Gao, C. et al. Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis. Int. J. Nursing Sci. 7(2), 238–247 (2020).
doi: 10.1016/j.ijnss.2020.03.007

Auteurs

Meseret Manaye (M)

Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, PO. Box: 79, Bahir Dar, Ethiopia.

Ergoye Melese (E)

Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, PO. Box: 79, Bahir Dar, Ethiopia.

Gizachew Tadesse Wassie (GT)

Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, PO. Box: 79, Bahir Dar, Ethiopia. leulgzat@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH